For the past year, a small California startup has been touting its technology as a possible treatment for Duchenne muscular dystrophy and potentially other genetic disorders.
The company, Sonothera, lacks clinical data but has presented animal studies that have left many experts astonished.
“I find it hard to believe,” said Eric Olson, chair of molecular biology at UT‑Southwestern Medical Center. “It seems a bit too good to be true,” added Jeffrey Chamberlain, a veteran Duchenne gene‑therapy researcher at the University of Washington.
Also Read
- Cyclosporiasis Outbreak Traced to Taylor Farms Iceberg Lettuce Distributed to Taco Bell Locations
- Committee Endorses Accelerated Prior Authorization Reform for Medicare Advantage
- New CMS Proposal Could Restrict Third‑Party Remote Patient Monitoring Services
- Eli Lilly Bolsters Psychedelics Portfolio with $2.8 Billion Purchase of AtaiBeckley